This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, M. E.
Right arrow Articles by Schmitz, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, M. E.
Right arrow Articles by Schmitz, F.-J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1999, p. 421-423, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus Strains

Mark E. Jones,1,dagger Maarten R. Visser,1 Miriam Klootwijk,1 Peter Heisig,2 Jan Verhoef,1 and Franz-Josef Schmitz1,*

Eijkman-Winkler Institute for Clinical Microbiology, University Hospital Utrecht, Utrecht, The Netherlands,1 and Department of Pharmaceutical Microbiology, University of Bonn, Bonn, Germany2

Received 27 July 1998/Returned for modification 1 September 1998/Accepted 16 November 1998

The activities of eight fluoroquinolones and linezolid, quinupristin-dalfopristin (Synercid), gentamicin, and vancomycin were tested against 96 ciprofloxacin-susceptible and 205 ciprofloxacin-resistant Staphylococcus aureus strains. Overall, clinafloxacin, followed by moxifloxacin and trovafloxacin, was the most active quinolone tested. For all isolates, linezolid and quinupristin-dalfopristin showed activities that were at least comparable to vancomycin, with no cross-resistance to any other test compound.

* Corresponding author. Mailing address: Eijkman-Winkler Institute for Clinical Microbiology, University Hospital Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. Phone: 31 30 250 7625. Fax: 31 30 254 1770.

dagger Present address: MRL Pharmaceutical Services, Utrecht 3554 XD, The Netherlands.

Antimicrobial Agents and Chemotherapy, February 1999, p. 421-423, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lipsky, B. A., Giordano, P., Choudhri, S., Song, J. (2007). Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 60: 370-376 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Y., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2005). Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones. Antimicrob. Agents Chemother. 49: 2642-2647 [Abstract] [Full Text]  
  • Jacobs, M. R., Bajaksouzian, S., Windau, A., Appelbaum, P. C., Patel, M. V., Gupte, S. V., Bhagwat, S. S., De Souza, N. J., Khorakiwala, H. F. (2004). In Vitro Activity of the New Quinolone WCK 771 against Staphylococci. Antimicrob. Agents Chemother. 48: 3338-3342 [Abstract] [Full Text]  
  • Bronner, S., Jehl, F., Peter, J.-D., Ploy, M.-C., Renault, C., Arvis, P., Monteil, H., Prevost, G. (2003). Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors. Antimicrob. Agents Chemother. 47: 1621-1629 [Abstract] [Full Text]  
  • Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Sahm, D. F. (2002). Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release. Antimicrob. Agents Chemother. 46: 1989-1992 [Abstract] [Full Text]  
  • Gander, S., Hayward, K., Finch, R. (2002). An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 49: 301-308 [Abstract] [Full Text]  
  • Betriu, C., Redondo, M., Boloix, A., Gomez, M., Culebras, E., Picazo, J. J. (2001). Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 48: 911-913 [Abstract] [Full Text]  
  • Entenza, J. M., Que, Y. A., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2001). Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance. Antimicrob. Agents Chemother. 45: 3076-3083 [Abstract] [Full Text]  
  • Dailey, C. F., Dileto-Fang, C. L., Buchanan, L. V., Oramas-Shirey, M. P., Batts, D. H., Ford, C. W., Gibson, J. K. (2001). Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2304-2308 [Abstract] [Full Text]  
  • Drago, L., De Vecchi, E., Mombelli, B., Nicola, L., Valli, M., Gismondo, M. R. (2001). Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 48: 37-45 [Abstract] [Full Text]  
  • Linde, H.-J., Schmidt, M., Fuchs, E., Reischl, U., Niller, H.-H., Lehn, N. (2001). In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci. Antimicrob. Agents Chemother. 45: 1553-1557 [Abstract] [Full Text]  
  • Giamarellou, H., Bassaris, H. P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E., Zoumbos, N. (2000). Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrob. Agents Chemother. 44: 3264-3271 [Abstract] [Full Text]  
  • Wright, D. H., Brown, G. H., Peterson, M. L., Rotschafer, J. C. (2000). Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46: 669-683 [Abstract] [Full Text]  
  • Drew, R. H., Perfect, J. R., Srinath, L., Kurkimilis, E., Dowzicky, M., Talbot, G. H., for the Synercid Emergency-Use Study Group, (2000). Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 46: 775-784 [Abstract] [Full Text]  
  • Fuchs, P. C., Barry, A. L., Brown, S. D. (2000). Bactericidal Activity of Quinupristin-Dalfopristin against Staphylococcus aureus: Clindamycin Susceptibility as a Surrogate Indicator. Antimicrob. Agents Chemother. 44: 2880-2882 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»